BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun 2016;7:13019. [PMID: 27698471 DOI: 10.1038/ncomms13019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Duo Y, Bao S, He L, Ling K, Luo J, Zhang Y, Huang H, Zhang H, Yu X. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. Int J Nanomedicine 2017;12:6239-57. [PMID: 28894364 DOI: 10.2147/IJN.S143293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 6.8] [Reference Citation Analysis]
2 Dong R, Ji J, Liu H, He X. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases. Crit Rev Oncol Hematol 2019;143:20-6. [PMID: 31449983 DOI: 10.1016/j.critrevonc.2019.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Xuan W, Peng Y, Deng Z, Peng T, Kuai H, Li Y, He J, Jin C, Liu Y, Wang R, Tan W. A basic insight into aptamer-drug conjugates (ApDCs). Biomaterials 2018;182:216-26. [PMID: 30138784 DOI: 10.1016/j.biomaterials.2018.08.021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
4 Falls KC, Sharma RA, Lawrence YR, Amos RA, Advani SJ, Ahmed MM, Vikram B, Coleman CN, Prasanna PG. Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico. Radiat Res 2018;190:350-60. [PMID: 30280985 DOI: 10.1667/RR15121.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
5 Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo PE, Azria D, Pèlegrin A, Larbouret C, Chardès T. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer 2019;145:1838-51. [PMID: 30882895 DOI: 10.1002/ijc.32273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Čermák V, Dostál V, Jelínek M, Libusová L, Kovář J, Rösel D, Brábek J. Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 2020;99:151075. [PMID: 32414588 DOI: 10.1016/j.ejcb.2020.151075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
7 Gouveia AG, Chan DCW, Hoskin PJ, Marta GN, Trippa F, Maranzano E, Chow E, Silva MF. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. Radiother Oncol 2021;163:55-67. [PMID: 34333087 DOI: 10.1016/j.radonc.2021.07.022] [Reference Citation Analysis]
8 Cerviño LI, Soultan D, Advani SJ, Cornell M, Yock A, Pettersson N, Song WY, Aguilera J, Murphy J, Hoh C, James C, Paravati A, Coope R, Gill B, Moiseenko V. An in vitro study for the dosimetric and radiobiological validation of respiratory gating in conventional and hypofractionated radiotherapy of the lung: effect of dose, dose rate, and breathing pattern. Phys Med Biol 2019;64:135009. [PMID: 31189137 DOI: 10.1088/1361-6560/ab2940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Mol Cancer Ther 2020;19:157-67. [PMID: 31597712 DOI: 10.1158/1535-7163.MCT-18-1302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Rev Mater 2017;2:17024. [PMID: 29075517 DOI: 10.1038/natrevmats.2017.24] [Cited by in Crossref: 516] [Cited by in F6Publishing: 487] [Article Influence: 129.0] [Reference Citation Analysis]
11 Zhang L, Jing D, Jiang N, Rojalin T, Baehr CM, Zhang D, Xiao W, Wu Y, Cong Z, Li JJ, Li Y, Wang L, Lam KS. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol 2020;15:145-53. [PMID: 31988501 DOI: 10.1038/s41565-019-0626-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 38.0] [Reference Citation Analysis]
12 Liu L, Chen W, Zhang R, Wang Y, Liu P, Lian X, Zhang F, Wang Y, Ma W. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress. Cancer Biol Med 2020;17:910-22. [PMID: 33299643 DOI: 10.20892/j.issn.2095-3941.2020.0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xia L, Wen L, Qin Y, Dobson HE, Zhang T, Comer FI, Hinrichs MJ, Oberst MD, Coats SR, Chang AE, Liu Y, Bao Y, Dai F, Wicha MS, Li Q. HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells. Cell Chem Biol 2021;28:610-624.e5. [PMID: 33711257 DOI: 10.1016/j.chembiol.2021.02.013] [Reference Citation Analysis]
14 Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials 2020;248:120032. [PMID: 32304937 DOI: 10.1016/j.biomaterials.2020.120032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Marazzi F, Orlandi A, Manfrida S, Masiello V, Di Leone A, Massaccesi M, Moschella F, Franceschini G, Bria E, Gambacorta MA, Masetti R, Tortora G, Valentini V. Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. Cancers (Basel) 2020;12:E2390. [PMID: 32846945 DOI: 10.3390/cancers12092390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Martin C, Kizlik-Masson C, Pèlegrin A, Watier H, Viaud-Massuard MC, Joubert N. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France. MAbs 2018;10:210-21. [PMID: 29239690 DOI: 10.1080/19420862.2017.1412130] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
17 He Z, Tian S, Gao Y, Meng F, Luo L. Luminescent AIE Dots for Anticancer Photodynamic Therapy. Front Chem 2021;9:672917. [PMID: 34113602 DOI: 10.3389/fchem.2021.672917] [Reference Citation Analysis]
18 Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol 2017;95:347-55. [PMID: 28138156 DOI: 10.1038/icb.2017.6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 21.8] [Reference Citation Analysis]
19 Wang Q, Gavin W, Masiello N, Tran KB, Laible G, Shepherd PR. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. Biotechnol Rep (Amst) 2020;28:e00533. [PMID: 33024714 DOI: 10.1016/j.btre.2020.e00533] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol 2021;119:105366. [PMID: 34091189 DOI: 10.1016/j.oraloncology.2021.105366] [Reference Citation Analysis]
21 DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev 2019;144:35-56. [PMID: 31279729 DOI: 10.1016/j.addr.2019.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
22 Yu CYY, Xu H, Ji S, Kwok RTK, Lam JWY, Li X, Krishnan S, Ding D, Tang BZ. Mitochondrion-Anchoring Photosensitizer with Aggregation-Induced Emission Characteristics Synergistically Boosts the Radiosensitivity of Cancer Cells to Ionizing Radiation. Adv Mater 2017;29:1606167. [DOI: 10.1002/adma.201606167] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 35.5] [Reference Citation Analysis]
23 Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, Mégnin-chanet F, Kirova Y. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiotherapy and Oncology 2017;124:190-9. [DOI: 10.1016/j.radonc.2017.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
24 Damuka N, Orr M, Czoty PW, Weiner JL, Martin TJ, Nader MA, Bansode AH, Liyana Pathirannahel BS, Mintz A, Macauley SL, Craft S, Solingapuram Sai KK. Effect of ethanol and cocaine on [11C]MPC-6827 uptake in SH-SY5Y cells. Mol Biol Rep 2021;48:3871-6. [PMID: 33880672 DOI: 10.1007/s11033-021-06336-7] [Reference Citation Analysis]
25 Gonda K, Negishi H, Takano-Kasuya M, Kitamura N, Furusawa N, Nakano Y, Hamada Y, Tokunaga M, Higuchi H, Tada H, Ishida T. Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues. Transl Oncol 2020;13:100764. [PMID: 32403030 DOI: 10.1016/j.tranon.2020.100764] [Reference Citation Analysis]
26 Conibear AC, Schmid A, Kamalov M, Becker CFW, Bello C. Recent Advances in Peptide-Based Approaches for Cancer Treatment. Curr Med Chem 2020;27:1174-205. [PMID: 29173146 DOI: 10.2174/0929867325666171123204851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
27 Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res 2018;132:47-68. [PMID: 29604436 DOI: 10.1016/j.phrs.2018.03.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
28 Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 2021;24:567-76. [PMID: 33646464 DOI: 10.1007/s10120-021-01164-x] [Reference Citation Analysis]
29 Qi J, Chen C, Ding D, Tang BZ. Aggregation-Induced Emission Luminogens: Union Is Strength, Gathering Illuminates Healthcare. Adv Healthcare Mater 2018;7:1800477. [DOI: 10.1002/adhm.201800477] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 29.0] [Reference Citation Analysis]
30 Wang H, Mu X, He H, Zhang XD. Cancer Radiosensitizers. Trends Pharmacol Sci 2018;39:24-48. [PMID: 29224916 DOI: 10.1016/j.tips.2017.11.003] [Cited by in Crossref: 162] [Cited by in F6Publishing: 147] [Article Influence: 40.5] [Reference Citation Analysis]
31 Mortensen MR, Skovsgaard MB, Okholm AH, Scavenius C, Dupont DM, Rosen CB, Enghild JJ, Kjems J, Gothelf KV. Small-Molecule Probes for Affinity-Guided Introduction of Biocompatible Handles on Metal-Binding Proteins. Bioconjugate Chem 2018;29:3016-25. [DOI: 10.1021/acs.bioconjchem.8b00424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]